Articles tagged with Clinical Trials
A new library of healthy participants' neuroimaging data has been created to aid in the diagnosis and treatment of traumatic brain injury (TBI). The Normative Neuroimaging Library consists of data from approximately 1900 individuals, providing a comprehensive dataset for clinicians and researchers.
A Phase 1/2 clinical trial found significant vision improvements in patients with Leber congenital amaurosis, a rare inherited condition causing early childhood blindness. The gene therapy, ATSN-101, demonstrated efficacy in correcting genetic mutations and restoring vision for up to 12 months.
Researchers developed a gene therapy that restored useful vision to most patients with Leber congenital amaurosis type I, a rare inherited blindness. The treatment showed a 10,000-fold improvement in light sensitivity and improved navigation abilities in patients who received the highest dose.
A study found that RSV vaccination significantly reduced hospitalization risk among adults 60+ in the US, offering protection against severe RSV disease. The vaccine demonstrated effectiveness in high-risk populations, including those over 75 and with immunocompromising conditions.
A team at NUS Yong Loo Lin School of Medicine leveraged an artificial intelligence-derived platform, CURATE.AI, to guide treatment for a patient with Waldenström macroglobulinemia, a rare blood disorder. The trial demonstrated substantial improvement in red blood cell levels and minimised side effects.
A global therapeutics development coalition is proposed to invigorate the pipeline and drive advocacy for increased investment. The coalition aims to develop two Phase-2 ready therapeutics for virus families of pandemic potential, with a focus on equitable access.
A clinical trial led by Washington University School of Medicine found that two anti-coagulant drugs did not improve outcomes for patients who received vessel-clearing interventions after a blood clot in the brain. The study aimed to test whether adding these medications could prevent further clots, but results showed no benefit.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
The FINEARTS-HF trial demonstrates finerenone's benefits in reducing worsening heart failure events and mortality in patients with mildly reduced or preserved ejection fraction. Finerenone significantly reduces total worsening HF events compared to placebo, but shows non-significant reductions in cardiovascular death.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
A randomized, placebo-controlled trial found finerenone improved outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. The drug also showed benefits regardless of the ejection fraction and even in patients on other approved therapies.
The NOTION-3 trial demonstrates that PCI plus TAVI is beneficial for patients with CAD, reducing MI and urgent revascularisation. The study suggests that performing PCI should be recommended for patients undergoing TAVI with CAD.
Treatment with prehospital pulse-dose glucocorticoid improved acute parameters, but did not reduce final infarct size after 3 months. The trial was likely underpowered due to smaller-than-anticipated final infarct sizes.
Sacubitril/valsartan significantly reduced hospitalization for any reason, particularly in patients with a left ventricular ejection fraction below normal. Lower rates of cardiac and pulmonary hospitalizations were also observed in this patient population.
Researchers at the University of Calgary are conducting a clinical trial using probenecid, an anti-gout medication, to treat debilitating opioid withdrawal symptoms. The study's lead authors aim to develop a potential treatment for the disabling symptoms of opioid withdrawal, which can be crippling.
A study emulated a clinical trial using real-world UK healthcare data to explore treatment effects in patients with atrial fibrillation. The method found similar outcomes between apixaban and warfarin, but with differences linked to ethnicity and medication use.
The National Institutes of Health has awarded $15.5 million to establish a national network structure to include more nursing home residents in clinical trials. The NEXT STEPs initiative aims to remove barriers to participation and increase the quality of clinical trials conducted in nursing homes.
A new non-hormonal hot flash treatment has been shown to significantly reduce symptom frequency and severity within weeks, while also improving sleep quality and overall well-being. The investigational drug elinzanetant was found to have a favorable safety profile with mild side effects.
Elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated significant reductions in vasomotor symptoms frequency and severity vs placebo in postmenopausal individuals with moderate to severe VMS. The treatment also improved sleep disturbances and menopause-related quality of life, with a favorable safety profile.
A clinical study confirmed the safety of aceneuramic acid in treating distal myopathy with rimmed vacuoles (GNE myopathy), a rare disease causing progressive muscle weakness. The treatment, developed for an ultra-orphan drug, showed efficacy and was approved by Japan's Ministry of Health, Labour and Welfare.
A disproportionality analysis of World Health Organization data revealed a signal of semaglutide-associated suicidal ideation, particularly among patients with co-reported antidepressant use. This finding warrants urgent clarification and highlights the need for further research on the safety profile of semaglutide.
Scalable telehealth mindfulness-based interventions show promise in treating chronic pain by improving function and reducing symptoms. The low-resource approach could accelerate the adoption of nonpharmacological pain treatment in healthcare systems.
A study examining tecovirimat's effectiveness on mpox in the DRC found the drug safe but showed no significant impact on lesion duration. The trial, sponsored by the NIH and co-led with the DRC, resulted in lower mortality rates among participants compared to reported cases.
A new vaccine has shown to protect mothers from malaria during pregnancy and for up to two transmission seasons without booster doses. The vaccine was well-tolerated and safe for both the mothers and their offspring, with no differences in adverse events compared to placebo.
A malaria vaccine candidate has demonstrated sustained protection against parasite infection and clinical malaria over two years without a booster dose. The vaccine significantly protected women from malaria in pregnancy, offering new strategies to prevent the disease in vulnerable populations.
Researchers developed a new brain-computer interface that translates brain signals into speech with up to 97% accuracy, enabling a man with amyotrophic lateral sclerosis (ALS) to communicate with friends and family. The system was tested in real-time conversations with continuous updates, achieving high word accuracy rates.
A clinical trial shows that JAK inhibitors improve autoimmune conditions such as alopecia areata, atopic dermatitis, and psoriasis in people with Down syndrome. The study also observed improvements in arthritis and decreased biomarkers of autoimmune thyroid disease.
A clinical trial in Denmark found that offering women further screening opportunities during breast cancer screenings significantly increased their participation and enabled early diagnosis of other cancers. The study used a cluster-randomized crossover design and involved over 27,000 participants.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
A recent study by Neda Akhavan found that baked potatoes can help lower blood sugar and improve body composition in adults with Type 2 diabetes. The study, which involved 24 participants, showed a modest decrease in fasting blood glucose levels and improvements in waist circumference and resting heart rate.
A new study found significant improvements in aerobic fitness after 12 weeks of high-intensity interval training sessions compared to traditional, moderate exercise. Researchers suggest this time-efficient approach can be safely and effectively implemented in clinical practice for stroke survivors.
A large clinical food trial will be conducted to test the effects of a combination of probiotics and prebiotics on bone health in women aged 60 years and above. The study aims to develop potentially safe and inexpensive dietary interventions for osteopenia and osteoporosis.
A UofL cardiologist is leading a Phase II clinical trial of a new stem cell therapy for heart failure, the first in the US to use intravenous delivery. The trial aims to determine whether one or multiple doses of mesenchymal stem cells improve health and quality of life for patients.
A clinical study in Birmingham has found that nipocalimab can improve the survival rate of unborn babies with rare fetal anaemia. The majority of pregnant patients who received nipocalimab gave birth at or after 32 weeks without needing an intrauterine transfusion, resulting in a perinatal survival rate of 92%.
Researchers analyzed data from 63,700 patients in five clinical trials to understand the impact of clonal hematopoiesis of indeterminate potential (CHIP) on heart disease. They found that patients with CHIP had a 30% higher risk of initial heart attacks but not recurrent events.
A clinical trial found that fish oil supplements slowed neuronal integrity breakdown in older adults with the APOE4 gene variant, a risk factor for Alzheimer's disease. The study showed no benefit for all older adults, but suggested omega-3 fatty acids may be useful for prevention.
Researchers at Wake Forest University School of Medicine are studying the effectiveness of non-pharmacological treatments for migraine, which affects nearly half of those with the condition and leads to significant disability. The five-year study aims to identify therapies that target long-term efficacy and safety.
A dual-chamber wireless pacemaker demonstrates reliable performance over three months, synchronizing contraction of the upper and lower heart chambers 98% of the time. The device continues to work well even when patients engage in activities or have elevated heart rates.
The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.
Tumors with mutations in ERCC2, ATM, or RB1 genes were more likely to be eliminated by cisplatin-based chemotherapy. The study found a correlation between these gene mutations and complete pathologic response to neoadjuvant chemotherapy.
A recent study published in ESC Heart Failure found that kidney dysfunction can be used as a criterion to stratify patients requiring implantable defibrillators. The research identified two key independent predictors for the risk of sudden cardiac death: left ventricular ejection fraction and estimated glomerular filtration rate.
Researchers found that combining plasma p-tau217 and Aβ42/40 levels could predict early brain Aβ accumulation in people with subthreshold Aβ accumulation. These biomarkers may help screen participants for primary prevention trials.
A randomized clinical trial found that posterior foraminotomy provides outcomes comparable to those of the more commonly performed anterior cervical discectomy. The two-year surgical success rate was 81% in patients assigned to posterior surgery, similar to 74% in the anterior group.
Research from Bentley University shows that biotechnology companies can maintain current levels of new drug approvals in face of global revenue reductions. Strategic distribution of cost reductions and continued investment in early-stage development by biotech firms sustain pipeline, contradicting industry claims.
A new study found that two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients. Medicaid expansion under the ACA alone did not improve diversity, but states with pre-existing mandates requiring coverage of clinical trial costs saw a significant increase.
The Wake Forest University School of Medicine has been awarded a $28.2 million grant from the National Institutes of Health to accelerate the translation of scientific discoveries. The grant will support initiatives such as rapid response to health emergencies and the recruitment of diverse academic learning health system workforce.
A clinical trial found that fecal microbiota transplants can boost the effectiveness of immunotherapy in a range of gastrointestinal cancers. The study identified specific bacterial strains associated with better or worse responses, and showed promise for improving treatment outcomes.
Researchers found that personalized text messages effectively increased physical activity among patients after significant heart events, with Apple Watch users showing a 10% increase in step count. However, the benefits later tapered off as patients became accustomed to the messages.
Researchers assessed botulinumtoxin-A treatment to improve walking capacity in children with cerebral palsy. The trial found some evidence of reduced calf pain and delayed improvement in energy cost, but no significant benefit for overall walking ease.
Researchers at KAUST have developed NanoRanger, an accurate and rapid method for genetically diagnosing Mendelian genetic disorders. This breakthrough enables diagnosis in just 12 minutes, providing a detailed picture of the genomic disorder.
The A4 study, a large clinical trial of pre-symptomatic Alzheimer’s disease, has yielded key insights into the condition. Researchers have collected extensive data on brain scans, blood samples, genetic information and cognitive tests from over 7,500 participants.
The PrEPVacc HIV vaccine trial found no significant reduction in HIV infections among participants. The study reported more infections in the vaccine arms compared to the placebo groups, but the results are inconclusive due to wide statistical confidence intervals.
A randomized clinical trial found that overground robot-assisted gait training using a wearable robot significantly improved gross motor function and gait pattern in children with cerebral palsy. The study suggests that this type of assistance may complement standard rehabilitation by providing adequate support.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
A randomized crossover trial found that a joint-AI model improved clinical diagnosis, but future trials are warranted to confirm its effectiveness. The AI model demonstrated positive human-AI interaction, suggesting its potential to facilitate accurate diagnoses.
Researchers found that subretinal adeno-associated virus 8 injections trigger proinflammatory T-cell responses, but co-injection of immunodominant peptides can modulate the immune system. This study suggests a new approach to AAV gene therapy for retinal diseases.
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
A new approach in vaccine research, adaptive platform trials (APTs), offers a flexible adjustment of study design during ongoing clinical trials. This allows for quick adaptation to new developments and enables the recruitment of large numbers of participants across different countries.
The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.
Researchers discuss HER2 in breast cancer, highlighting the prognostic and predictive factors. They found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer, challenging the long-held view that HER2-negative tumors do not benefit from trastuzumab-based therapy.